148 related articles for article (PubMed ID: 32526884)
1. Inhibition of Patched Drug Efflux Increases Vemurafenib Effectiveness against Resistant Braf
Signetti L; Elizarov N; Simsir M; Paquet A; Douguet D; Labbal F; Debayle D; Di Giorgio A; Biou V; Girard C; Duca M; Bretillon L; Bertolotto C; Verrier B; Azoulay S; Mus-Veteau I
Cancers (Basel); 2020 Jun; 12(6):. PubMed ID: 32526884
[TBL] [Abstract][Full Text] [Related]
2. Methiothepin Increases Chemotherapy Efficacy against Resistant Melanoma Cells.
Durand N; Simsir M; Signetti L; Labbal F; Ballotti R; Mus-Veteau I
Molecules; 2021 Mar; 26(7):. PubMed ID: 33810240
[TBL] [Abstract][Full Text] [Related]
3.
Kulkarni A; Al-Hraishawi H; Simhadri S; Hirshfield KM; Chen S; Pine S; Jeyamohan C; Sokol L; Ali S; Teo ML; White E; Rodriguez-Rodriguez L; Mehnert JM; Ganesan S
Clin Cancer Res; 2017 Sep; 23(18):5631-5638. PubMed ID: 28539463
[No Abstract] [Full Text] [Related]
4. Natural paniceins from mediterranean sponge inhibit the multidrug resistance activity of Patched and increase chemotherapy efficiency on melanoma cells.
Fiorini L; Tribalat MA; Sauvard L; Cazareth J; Lalli E; Broutin I; Thomas OP; Mus-Veteau I
Oncotarget; 2015 Sep; 6(26):22282-97. PubMed ID: 26068979
[TBL] [Abstract][Full Text] [Related]
5. Astemizole Sensitizes Adrenocortical Carcinoma Cells to Doxorubicin by Inhibiting Patched Drug Efflux Activity.
Hasanovic A; Simsir M; Choveau FS; Lalli E; Mus-Veteau I
Biomedicines; 2020 Jul; 8(8):. PubMed ID: 32751066
[TBL] [Abstract][Full Text] [Related]
6. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
Ravnan MC; Matalka MS
Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
[TBL] [Abstract][Full Text] [Related]
7. An autophagy-driven pathway of ATP secretion supports the aggressive phenotype of BRAF
Martin S; Dudek-Peric AM; Garg AD; Roose H; Demirsoy S; Van Eygen S; Mertens F; Vangheluwe P; Vankelecom H; Agostinis P
Autophagy; 2017 Sep; 13(9):1512-1527. PubMed ID: 28722539
[TBL] [Abstract][Full Text] [Related]
8. Differential expression of ABCB5 in BRAF inhibitor-resistant melanoma cell lines.
Xiao J; Egger ME; McMasters KM; Hao H
BMC Cancer; 2018 Jun; 18(1):675. PubMed ID: 29929490
[TBL] [Abstract][Full Text] [Related]
9. Vemurafenib.
Garbe C; Abusaif S; Eigentler TK
Recent Results Cancer Res; 2014; 201():215-25. PubMed ID: 24756795
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of BRAF inhibitor vemurafenib in preclinical models of BRAF-mutant colorectal cancer.
Yang H; Higgins B; Kolinsky K; Packman K; Bradley WD; Lee RJ; Schostack K; Simcox ME; Kopetz S; Heimbrook D; Lestini B; Bollag G; Su F
Cancer Res; 2012 Feb; 72(3):779-89. PubMed ID: 22180495
[TBL] [Abstract][Full Text] [Related]
11. Resveratrol Overcomes Cellular Resistance to Vemurafenib Through Dephosphorylation of AKT in BRAF-mutated Melanoma Cells.
Luo H; Umebayashi M; Doi K; Morisaki T; Shirasawa S; Tsunoda T
Anticancer Res; 2016 Jul; 36(7):3585-9. PubMed ID: 27354627
[TBL] [Abstract][Full Text] [Related]
12. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
[TBL] [Abstract][Full Text] [Related]
13. The pharmacological impact of ATP-binding cassette drug transporters on vemurafenib-based therapy.
Wu CP; V Ambudkar S
Acta Pharm Sin B; 2014 Apr; 4(2):105-11. PubMed ID: 26579371
[TBL] [Abstract][Full Text] [Related]
14. Pericytes Elicit Resistance to Vemurafenib and Sorafenib Therapy in Thyroid Carcinoma via the TSP-1/TGFβ1 Axis.
Prete A; Lo AS; Sadow PM; Bhasin SS; Antonello ZA; Vodopivec DM; Ullas S; Sims JN; Clohessy J; Dvorak AM; Sciuto T; Bhasin M; Murphy-Ullrich JE; Lawler J; Karumanchi SA; Nucera C
Clin Cancer Res; 2018 Dec; 24(23):6078-6097. PubMed ID: 30076136
[TBL] [Abstract][Full Text] [Related]
15. Reversal of Resistance in Targeted Therapy of Metastatic Melanoma: Lessons Learned from Vemurafenib (BRAF
Torres-Collado AX; Knott J; Jazirehi AR
Cancers (Basel); 2018 May; 10(6):. PubMed ID: 29795041
[TBL] [Abstract][Full Text] [Related]
16. Vemurafenib.
Garbe C; Eigentler TK
Recent Results Cancer Res; 2018; 211():77-89. PubMed ID: 30069761
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of vemurafenib-resistant melanoma by interference with pre-mRNA splicing.
Salton M; Kasprzak WK; Voss T; Shapiro BA; Poulikakos PI; Misteli T
Nat Commun; 2015 May; 6():7103. PubMed ID: 25971842
[TBL] [Abstract][Full Text] [Related]
18. Melanoma patient derived xenografts acquire distinct Vemurafenib resistance mechanisms.
Monsma DJ; Cherba DM; Eugster EE; Dylewski DL; Davidson PT; Peterson CA; Borgman AS; Winn ME; Dykema KJ; Webb CP; MacKeigan JP; Duesbery NS; Nickoloff BJ; Monks NR
Am J Cancer Res; 2015; 5(4):1507-18. PubMed ID: 26101714
[TBL] [Abstract][Full Text] [Related]
19. Identification of coexistence of BRAF V600E mutation and EZH2 gain specifically in melanoma as a promising target for combination therapy.
Yu H; Ma M; Yan J; Xu L; Yu J; Dai J; Xu T; Tang H; Wu X; Li S; Lian B; Mao L; Chi Z; Cui C; Guo J; Kong Y
J Transl Med; 2017 Dec; 15(1):243. PubMed ID: 29202777
[TBL] [Abstract][Full Text] [Related]
20. A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.
Graziani G; Artuso S; De Luca A; Muzi A; Rotili D; Scimeca M; Atzori MG; Ceci C; Mai A; Leonetti C; Levati L; Bonanno E; Tentori L; Caccuri AM
Biochem Pharmacol; 2015 May; 95(1):16-27. PubMed ID: 25795251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
